Spatial proteomics finds CD155 and Endophilin-A1 as mediators of growth and invasion in medulloblastoma

Charles Capdeville¹, Linda Russo¹, David Penton², Jessica Migliavacca¹, Milica Zecevic¹, Alexandre Gries¹, Stephan CF Neuhauss², Michael A Grotzer³, Martin Baumgartner¹

The composition of the plasma membrane (PM)-associated proteome of tumor cells determines cell–cell and cell–matrix interactions and the response to environmental cues. Whether the PM-associated proteome impacts the phenotype of Medulloblastoma (MB) tumor cells and how it adapts in response to growth factor cues is poorly understood. Using a spatial proteomics approach, we observed that hepatocyte growth factor (HGF)-induced activation of the receptor tyrosine kinase c-MET in MB cells changes the abundance of transmembrane and membrane-associated proteins. The depletion of MAP4K4, a pro-migratory effector kinase downstream of c-MET, leads to a specific decrease of the adhesion and immunomodulatory receptor CD155 and of components of the fast-endophilin-mediated endocytosis (FEME) machinery in the PM-associated proteome of HGF-activated MB cells. The decreased surface expression of CD155 or of the fast-endophilin-mediated endocytosis effector endophilin-A1 reduces growth and invasiveness of MB tumor cells in the tissue context. These data thus describe a novel function of MAP4K4 in the control of the PM-associated proteome of tumor cells and identified two downstream effector mechanisms controlling proliferation and invasiveness of MB cells.

DOI 10.26508/lsa.202201380 | Received 21 January 2022 | Revised 18 February 2022 | Accepted 24 February 2022 | Published online 16 March 2022

Introduction

The plasma membrane (PM)-associated proteome is a dynamic interface of mammalian cells, which orchestrates interactions with the extracellular environment and transmits extracellular cues. This physical barrier regulates the transfer of chemical and mechanical information between extracellular and intracellular spaces. The net outcome of the functions of PM-associated proteins affects the cellular phenotype and the composition and biophysical structure of the extracellular microenvironment. The PM-associated proteome primarily consists of receptors, cell adhesion molecules, enzymes and ion channels (1), and their expression defines the strength and duration of signal transmission and how the cell interacts with its environment. Besides these transmembrane proteins, numerous proteins are associated with the PM either directly through lipid anchors, or indirectly by binding to transmembrane proteins. The diversity of proteins associated with the PM and their differential expression, localization, or regulation under pathological conditions such as cancer not only define the condition-specific biomarker landscape (2), but also constitutes a druggable repertoire of therapeutic targets to interfere with the oncogenic phenotype.

The PM-associated proteome of a cell is dynamically controlled through membrane turnover via endocytic uptake and exocytic fusion (3, 4), which involves the dynamic reorganization of the cortical cytoskeleton. Membrane trafficking and cytoskeleton reorganization are thus key processes that position chemical and mechanical sensors and enable the uptake of nutrients or extrusion of signal transmitters, thereby determining the cellular response to complex environments. Moreover, endocytosis and the sequential intracellular vesicular trafficking control adhesion turnover, signal transduction, consequently influencing the duration of mitogenic or motile phenotypes. De-regulation of physiological trafficking in tumor cells may thus contribute to cell transformation (5), and especially altered endocytic activity can broadly impact tumor cell growth, invasion and metastasis, and viability (6, 7).

Medulloblastoma (MB) is a malignant embryonal neuroepithelial tumor of the cerebellum with a high propensity to disseminate and metastasize within the central nervous system (8). Several omics studies described the genomic heterogeneity in MB, which is now classified into four subgroups with 12 subtypes in total (9, 10). Despite this molecular understanding of MB, the current standard therapy still consists of surgical resection of the tumor and craniospinal irradiation followed by chemotherapy (11). These anti-cancer therapies can have a devastating impact on the developing brain of the patients and can cause severe long-term side effects such as cognitive or mobility impairments (12). Thus, novel therapeutic options with phenotype-specific anti-tumor activity are
needed to replace or complement current treatments and reduce therapy-associated side effects.

The Ser/Thr kinase MAP4K4 is overexpressed in MB and contributes to the pro-invasive phenotype of MB cells downstream of HGF–cellular mesenchymal–epithelial transition factor (c-MET) stimulation (13, 14). c-MET receptor tyrosine kinase (RTK) activation caused increased membrane dynamics, increased endocytic uptake and the activation and turnover of integrin β1 adhesion receptor (13). Integrin activation and internalization of integrins are necessary for cell migration and invasion (15, 16). Internalization of activated RTKs and integrins furthermore modulates pathway activation at endosomal compartments (17, 18). Therefore, the condition-specific endocytic activity adds a layer of regulatory impact on tumor cell behavior.

Endocytic processes like synaptic vesicle endocytosis, receptor trafficking, apoptosis and mitochondrial network dynamics can be controlled by endophilins, which are members of the BAR (Bin/amphipathysn/Rvs) domain superfamily (19, 20). Dysregulation of these processes is associated with cancer or neurodegenerative diseases (19, 21). Endophilins were initially considered a peripheral component of clathrin-mediated endocytosis (22, 23). However, a novel clathrin-independent endocytic pathway based on endophilin-A subfamily activity, termed fast endophilin-mediated endocytosis (FEME) was described recently (21), and several studies also implicated endophilins in cell motility control (24, 25, 26). The endophilin-A1 (EndoA1) is almost exclusively expressed in brain tissue (27).

Indirect control of invasion by MAP4K4 via CD155 and EndoA1

How the PM proteome of MB cells is regulated in response to RTK activation, and which potential therapeutic targets may be represented in the dynamic PM compartment are unknown. Therefore, we used a spatial proteomics approach (28) and determined the PM-associated proteome of resting and RTK-activated MB cells. We addressed whether the pro-oncogenic activity of MAP4K4 could be coupled to RTK-induced, dynamic alterations in the PM proteome. This analysis allowed the identification of PM-associated proteins subjected to c-MET-induced spatial re-distribution and the identification of MAP4K4 as a regulator of this process. We describe MAP4K4-dependent alterations in PM association of solute carriers, ion channels and of immune modulatory receptors. Furthermore, we address underlying mechanisms and potential functional consequences of this regulation for cancer cell homeostasis and cancer cell motility.

Results

HGF-c-MET signaling promotes PM proteome reorganization in medulloblastoma cells

To determine changes in PM and PM-proximal association of proteins in response to growth factor stimulation, we used a PM-associated proteome analysis approach (Fig 1A). We used membrane-impermeable Sulfo-NHS-SS-biotin labeling of intact sgControl (sgCTL, sgc) and sgMAP4K4 (MAP4K4 knockout, sgM4, Fig 1A and B) MB tumor cells, followed by streptavidin protein capture and high-resolution mass spectrometry analysis (Fig 1A). The data generated a rather diverse set of proteins, which is available via ProteomeXchange with the identifier http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD030597. We observed no significant difference in the PM proteome between sgCTL and sgMAP4K4 cells under starved conditions (Fig S1C). Stimulation with HGF caused an alteration in protein abundance (Fig S1C and D), suggesting that growth factor stimulation alters the composition of PM-associated proteins. To specifically enrich for membrane or membrane-associated proteins, we filtered the data either by using the transmembrane prediction algorithm TMHMM (29) or by annotating the proteins according to their known subcellular localization (30). These stringent sorting criteria identified 952 TM proteins and 336 PM-annotated proteins, respectively (Fig 1A and Tables S1 and S2). In sgCTL cells, HGF stimulation decreased the abundance of a number of TM (Figs 1B and S1D and Table S3) or PM-annotated proteins (Figs 1B and S1D and Table S4). This indicated that either internalization of these proteins in response to c-MET activation is increased or recycling decreased. We previously found that internalization of activated c-MET depends on MAP4K4 (13). Therefore, we tested whether MAP4K4 could contribute to reduced PM association in cells, where c-MET is activated by HGF stimulation. By comparing HGF-stimulated sgCTL and sgMAP4K4 cells, we detected changes in the abundance of >1,500 proteins (fold change $>2$, adjusted $P$-value $< 0.2$, Figs 1C and S1F). Specifically, HGF stimulation in MAP4K4-depleted cells led to an increased abundance of TM proteins (Fig 1B and C and Table S3) and PM-annotated proteins (Fig 1B and C and Table S4), suggesting a regulatory function of MAP4K4 in PM localization of these proteins. A paradigmatic example is c-MET itself, which is internalized in a MAP4K4-dependent manner in DAOY cells (14) and detected at lower levels in the PM proteome in response to HGF stimulation in sgCTL cells (Fig 1D). MAP4K4 contributes to this process as depletion of MAP4K4 significantly increases c-MET abundance on the PM in HGF-stimulated cells. None of the five additional RTKs detected by mass-spectrometry displayed similar behavior (Fig 1D). We concluded from this experiment that c-MET activation triggers the turnover of PM-associated proteins and that MAP4K4 is indispensable for the turnover of a number of those proteins in MB cells. Gene ontology analysis of PM-associated proteins revealed MAP4K4 dependencies in several pathways controlling endo- and exocytotic activities of cells as well as immune cell recognition or solute exchange (Fig 1E). It also revealed that HGF stimulation in sgMAP4K4 cells increased PM association of proteins with reported implications in chemotherapy sensitivity/resistance (SLC29A1, SLC4A7, and LRRRC8) (31, 32) (Fig 1F and Table S3). Conversely, MAP4K4 depletion decreased PM association of proteins involved in tumor immune evasion (CD155, CD276, and HLA-G) (33, 34, 35), in solute influx regulation (CLIC1, SLCs, and ABCCs) (36, 37) and cell migration (CD155 and CD276) (33, 38) (Fig 1F and Tables S1–S4). In conclusion, we found that c-MET activation by HGF triggers reorganization of the PM-associated proteome in MB cells and that MAP4K4 is involved in the selective control of this process.

Altered transporter expression in MAP4K4-depleted cells does not significantly affect sensitivity to etoposide and lomustine

To better understand which protein functions are particularly affected by the altered PM-associated proteome, we annotated the filtered proteins using Protein Atlas (39, 40). We found that 223 of 952 transmembrane proteins (Fig S2A) and 84 of 336 PM proteins...
Figure 1. Hepatocyte growth factor (HGF)-c-MET signaling alters composition of plasma membrane (PM)-associated proteome.

(A) General workflow for cell-surface protein isolation, mass spectrometry and computational analysis used.

(B) Volcano plot of PM-associated proteins identified by deep mass-spectrometry analysis. Colored dots indicate proteins with predicted TM domain (blue, upper) or PM localization (red, lower). sgCTL: CRISPR/CAS-9 control guide RNA expressing cells; sgMAP4K4: CRISPR/CAS-9 MAP4K4-specific guide RNA expressing cells; + HGF: SFM supplemented with 20 ng/ml HGF for 30 min.

(C) Log2 Fold change of RAW, TM or PM protein comparisons between treatments. Green: positive fold change (increased association), red: negative fold change (decreased association).

(D) Quantification of the PM association of different receptor tyrosine kinases. Box plots display normalized z-score values extracted from all-group comparison of MS analysis. N = 4 independent experiments, min to max, * = P < 0.05 (mixed-effect analysis, with Sidák’s multiple comparisons test).

(E) Heat maps of Indirect control of invasion by MAP4K4 via CD155 and EndoA1 Capdeville et al. https://doi.org/10.26508/lsa.202201380 vol 5 | no 6 | e202201380 3 of 18
MAP4K4 controls PM association of ion transport proteins and prevents cell hyperpolarization in HGF-stimulated cells

We furthermore detected MAP4K4-dependent PM association of the chloride channel CLIC1 in HGF-stimulated cells (Figs 2A and S2F). CLIC1 contributes to MB proliferation in vitro, and CLIC1 depletion in MB tumor cell lines significantly reduces tumor cell growth in vivo (37). Gene expression analysis of several MB patient sample cohorts shows CLIC1 overexpression in the tumor samples compared with control tissues (Fig 2B). Importantly, this elevated CLIC1 expression is associated with worse outcomes in SHH- and Gr4 MB tumors (Fig 2C). In control cells, PM association of CLIC1 remains unaltered by HGF stimulation. In contrast, HGF stimulation of MAP4K4-depleted cells caused a significant drop of CLIC1 PM association (Fig 2A), suggesting that MAP4K4 is either necessary for CLIC1 transfer to or maintenance at the PM in growth factor-stimulated cells. Conversely, the PM association of the acetyl-CoA transporter SLC33A1, the H^+/Ca^2+/Mn^2+ exchanger TMEM165, the H^+/K^+ transporter ATPase ATP12A, the sodium bicarbonate co-transporter SLC4A7, the acetyl-CoA transporter SLC19A1 and the Na^+/K^+ transporter ATP1A3 is significantly increased in MAP4K4-depleted cells stimulated with HGF (Fig 2D). Using qRT-PCR we found no evidence that MAP4K4 depletion altered the mRNA expression of a selection of proteins identified in our study, indicating that altered PM association is not the consequence of altered transcriptional control (Fig S1B).

To investigate the significance of this HGF- and MAP4K4-dependent modulation of PM localization of ion channels in MB cell ion homeostasis, we performed whole-cell patch-clamp measurement of the electrical properties of sgCTL and sgMAP4K4 DAOY cells. Under starved conditions, MAP4K4 depletion led to an increased whole-cell current compared with control cells (Fig 2E). As we observed the most striking differences in PM association between sgCTL and sgMAP4K4 cells after HGF stimulation, we quantified the resting membrane potential (V_m) under these conditions. We found that HGF stimulation caused hyperpolarization of MAP4K4-depleted compared with control cells (Fig 2F). This last finding is in accordance with a more depolarized V_m in disseminating cancer cells, where hyperpolarization leads to a loss of metastatic potential (48). Taken together, these data indicated the implication of MAP4K4 in modulating PM association of ion transport proteins in growth factor-stimulated cells and that one consequence of this MAP4K4 function is to prevent hyperpolarization after HGF stimulation.

Reduced PM association of CD155 correlates with reduced invasion and motility of MB cells

We found differential PM association of the adhesion and immune-modulatory proteins CD155 and CD276 (Fig 1F). CD276 impacts colorectal cancer cell migration through the Jak2/Stat3/MMP-9 signaling pathway (38). CD155, also referred to as poliovirus receptor (PVR), is a member of the nectin-like family of proteins that can interact with integrins or RTKs and increases FAK, Ras, or RAP1 downstream signaling (49). CD155 is involved in cell adhesion, migration, proliferation, or immune regulation (33), and it is often up-regulated in tumors compared with healthy tissues (49). This renders CD155 particularly interesting in the context of tumor progression, where it could contribute to immune evasion and dissemination.

HGF stimulation in sgMAP4K4 cells causes reduced PM abundance of CD155 compared with sgCTL cells (Fig 3A). Decreased PM association of CD155 in MAP4K4 depleted cells is not the result of transcriptional control of CD155 (Fig 3B) or reduced protein expression (Fig S1E and H). HGF stimulation rather increased mRNA expression of CD155 both in sgCTL and sgMAP4K4 cells by 10–20% (Fig 3B), excluding the possibility that the decrease in CD155 PM association in HGF-stimulated sgMAP4K4 is a consequence of transcriptional repression. Combined these findings indicated that MAP4K4 is either required for the transfer or the maintenance of CD155 at the PM under conditions that trigger membrane dynamics and endocytic turnover.

To test the requirement of CD155 for HGF-induced collagen invasion, we performed a spheroid invasion assay (SIA) (50, 51) (Fig 3C)
Figure 2. MAP4K4 modulates the ion homeostasis of DAOY cells.
(A) Quantification of plasma membrane association of CLIC1 by MS. Box plots display normalized z-score values extracted from all-group comparison of MS analysis. N = 4 independent experiments, min to max, ** = adjusted \( P < 0.01 \) of one-way ANOVA.
(B) U133P Affymetrix gene chip microarray analysis of CLIC1 mRNA expression levels in normal brain tissue and MB tumor samples.
(C) Kaplan–Meier survival analyses in four MB subgroups relative to CLIC1 mRNA expression levels.
(D) Quantification of plasma membrane association of ion transport proteins by MS. Box plots display normalized z-score values extracted from all-group comparison of MS analysis. N = 4 independent experiment, min to max, * = adjusted \( P < 0.05 \), ** = adjusted \( P < 0.01 \) of one-way ANOVA.
(E) Whole-cell currents measured at holding potential ranging from −100 mV to +80 mV (in steps of 20 mV) in DAOY cells ± KO of MAP4K4. N = 13–16 cells measured independently.
(F) Quantification of the membrane potential of DAOY cells ± KO of MAP4K4 and ± HGF stimulation (20 ng/ml, 30 min) in normal [Cl\(^-\)] SFM medium. N = 8–16 cells measured independently.
using CD155-depleted DAOY cells (Fig S1G and H). We found that the reduction of CD155 expression stalled HGF-induced collagen I invasion. To corroborate the implication of CD155 in migration control with another cell line, we tested the effect of CD155 depletion on collagen I invasion in ONS-76 SHH MB cells. These cells invade independently of exogenous growth factor stimulation. We first confirmed CD155 depletion by siRNA using FACS (Fig 3D). We then found that CD155 depletion significantly reduced collagen I invasion.
invasion (Fig 3E) and that it also reduced proliferation of ONS-76 cells grown as spheres in 3D cultures (Fig S3A) without inducing cell death (Fig S3B). As the inhibition of proliferation by Mitomycin C did not block collagen I invasion in ONS-76 cells (Fig S3C), we concluded that the reduced disseminated cell count in the collagen invasion analysis of CD155-depleted cells is not primarily a consequence of reduced proliferation, but rather of a reduced migratory potential of these cells. To further test this possibility, we assessed the consequence of reduced CD155 expression on motility parameters more directly by single-cell analysis of CD155-depleted ONS-76 cells seeded on collagen I-coated plates. Cell movements were recorded by time-lapse video microscopy for 5 h. CD155 depletion reduced the average speed of ONS-76 cells by 50% (Fig 3F). Phenotypically, cells with decreased CD155 expression displayed increased circularity, increased area, and increased width to length ratio (Fig 3F). Taken together, these data identified the CD155 cell adhesion molecule as a promotor of proliferation, motility, and invasiveness in SHH MB cell models.

**CD155 is necessary for cerebellar tissue infiltration**

To assess whether CD155 depletion prevented cerebellar tissue infiltration and growth of MB cells, we implanted ONS-76-LA-EGFP tumor spheroids onto cerebellar slices and determined growth and invasion after tumor-cerebellar slice co-culture (52). After 48 h of co-culture, ONS-76-LA-EGFP cells transfected with siCTL displayed sheet-like infiltration of the surrounding brain tissue (Fig 3G). In contrast, spheroids of cells transfected with siCD155 did display a much-reduced invasive behavior and remained clustered at the site of initial spheroid positioning. As an indirect measure for tumor growth and invasion, we quantified the volume of the tumor cell clusters. We observed a ~2-fold reduction of the cluster volume in siCD155 transfected compared with siCTL cells (Figs 3G and S3D). Some cells in the siCD155 condition still display an invasive phenotype (Figs 3G and S3D), possibly because of variations in transfection efficiency at the single-cell level. We also evaluated tumor cell proliferation in the tissue-embedded tumor cell clusters using Edu incorporation. We found that depletion of CD155 caused a significant decrease in the number of proliferative cells in the ex vivo model, indicating that CD155 also contributes to proliferation in the tissue context (Figs 3G and S3D). Together, these findings demonstrate that the cell adhesion receptor CD155 contributes to tissue invasion and growth in SHH MB cells.

**Increased expression of MAP4K4 and EndoA1 in SHH MB**

MAP4K4 is overexpressed in MB patient tumor samples (14) and gene expression profiling of 763 primary MB samples (53) revealed that MAP4K4 expression correlates positively with genes involved in endocytosis control (Fig S4A). Interestingly, the strongest positive correlate with MAP4K4 expression among the endocytosis-regulating genes is SH3GL2 (EndoA1, r = 0.501), whereas expression of both CLTB (r = −0.228) and CLTC (r = −0.228) correlate negatively with MAP4K4 (Fig S4B). The highest positive correlation between SH3GL2 and MAP4K4 expression is observed in SHH MB tumors, where also CLTC and SH3GL2 expression correlate negatively (r = −0.144) (Fig 4A). Thus, decreased cell migration and altered surface proteome composition in MAP4K4-depleted cells could be mechanistically linked to a clathrin-independent mechanism of endocytosis downstream of HGF-c-MET signaling. A recent genonomic and proteomic analysis of a cohort of 218 pediatric brain tumors (54) revealed increased levels of MAP4K4, EndoA1, and EndoA3 among both protein and RNA levels—but not of EndoA2, in primary MB and ganglioglioma tumor samples (Fig S4C). These findings highlight high expression of endophilins in MB compared with other central nervous system tumors and pointed towards a potential importance of FEME (21) in this tumor type.

**MAP4K4 controls PM association and subcellular distribution of FEME regulators**

To explore whether MAP4K4 could be involved in PM localization of FEME components such as CIN85/SH3KBP1, CIP4, BIN1, and FBP17, four regulators of FEME priming (55), we compared their abundance in the different surface proteome samples we generated (Tables S1 and S2). We found that HGF stimulation caused a small increase in PM association of these proteins and of EndoA2 in control cells (Fig 4B). In contrast, PM association of CIN85/SH3KBP1, CIP4, BIN1 and EndoA2 decreased significantly in HGF-stimulated sgMAP4K4 cells, indicating that MAP4K4 controls membrane association of these proteins in cells with activated c-MET. We could not detect EndoA1 and EndoA3 in our proteomic samples. CIN85/SH3KBP1, CIP4, and FNBPI/FBP17 are considered critical mediators of FEME by priming the PM for endophilin A clustering (55). PM enrichment of these proteins in a MAP4K4-dependent manner in HGF-stimulated cells could thus indicate a link between MAP4K4 and FEME priming. In cells, CIP4 is detectable associated with dotted and filamentous structures that do not co-localize with F-actin (Fig 4C and D). The depletion of MAP4K4 alters the subcellular localization of CIP4 and causes CIP4 to accumulate in circular patches near cellular protrusions (Fig 4D). Depletion of EndoA1 phenocopies CIP4 accumulation in these patches (Fig 4D). Interestingly, we also observed the early endosome marker EEA1 in similar patches in control but not in MAP4K4- or EndoA1-depleted cells (Fig 55). Whereas this potential colocalization remains to be further investigated, we observed that depletion of EndoA1 or MAP4K4 led to a 20% reduction of EEA1 puncta per cell in a HGF stimulation-independent manner. This indicates that both EndoA1 and MAP4K4 enable formation of early endosomes and further corroborate the shared functionality of the two proteins in endocytosis regulation. Together, these results indicate the implication of MAP4K4 in membrane recruitment, cortical localization and organization of key regulators of FEME in HGF-stimulated cells, thereby possibly facilitating an effective FEME sequence (55) (Fig 4E).

**EndoA family proteins are required for cell motility and tissue invasion**

To determine whether endocytosis pathways (Fig S6A) are involved in HGF-induced migration control, we assessed the contributions of endocytic pathway components to the HGF-induced invasive phenotype. We used 25 siRNAs targeting 16 essential components of eight different endocytic pathways (Fig 5B). Down-regulation efficacy of the siRNAs was confirmed by qRT-PCR (Fig S6C) and HGF
induced transwell migration assessed using Boyden chamber assays (Fig 5A). Consistent with previous studies (13, 14), HGF stimulation increased the number of transmigrated cells (~2.7-fold increase). Depletion of dynamin 1 and 2 (DNM1 and DNM2) abrogated HGF-induced migration (Fig 5A), confirming a general role of endocytosis in migration control. Interestingly, depletion of endophilin A proteins completely abrogated (EndoA1) or drastically reduced (EndoA2 and EndoA3) HGF-induced cell migration (Fig 5A).
contrast, depletion of clathrin or caveolin, two essential components of endocytic pathways for GF signaling (56), did not prevent or reduce HGF-induced DAOY cell migration. Similarly, depletion of two regulators of micropinocytosis, CTBP1 and RAC1 (57), did also not block HGF-induced migration. Both non-transfected and siCTL transfected cells showed similar levels of proliferation up to 72 h, whereas depletion of any of the three EndoA proteins or of DNM1 exhibited even moderately increased levels of proliferation (Fig...
S6D). These data exclude a proliferation defect as the underlying cause of reduced transwell migration in siEndoA1/2/3- or siDNM1-transfected cells and indicate the implication of EndoA1 and DNM1 in cell migration control.

**EndoA1 is required for 3D collagen I matrix invasion**

We next tested whether depletion of EndoA1, DNM1, or clathrin heavy chain (CLTC) also affects 3D collagen I invasiveness of MB cells (Figs S5B and S6E and F). HGF caused a robust increase in the number of cells disseminating into the collagen I matrix and increased the distance of invasion (~6.8-fold increase compared to untreated control). Depletion of EndoA1 or DNM1 significantly reduced HGF-induced collagen I invasion, whereas depletion of CLTC had no effect, indicating that EndoA1 functions in clathrin-independent endocytosis. Consistent with a conserved role of EndoA1 in migration control, depletion of EndoA1 also reduced (~1.6-fold decrease) collagen I invasion of ONS-76 cells (Fig 5C). Depletion of MAP4K4 caused also some, albeit insignificant, reduction in EndoA1 expression (Fig S6F). To determine whether a compensatory mechanism mediated by EndoA2 or EndoA3 (24) may be active in our cell model, we depleted all endophilin A proteins simultaneously (TKD). We found that endophilin TKD abrogates HGF-induced cell migration in DAOY cells moderately more effectively than siEndoA1 alone (Fig 5D). We concluded that EndoA2 or EndoA3 contribute to migration control in MB cells, and that EndoA1 is the most relevant endophilin in our cell model. In conclusion, we found that EndoA1 mediates a migratory phenotype in MB cells, possibly through a mechanism involving clathrin-independent endocytosis.

**EndoA1 depletion reduces tissue invasion**

We next assessed the role of EndoA1 in tumor growth and invasion control in the tissue context with tumor-cerebellar slice co-culture experiments using ONS-76-LA-EGFP cells. Depletion of EndoA1 markedly reduced cerebellum tissue infiltration and prevented the formation of streams of invading cells, which are highly characteristic for this type of MB tumor cell (Fig 5E, panel a). Individual EndoA1-depleted tumor cells still displayed invasion at the border of the spheres. However, the morphology of these cells appeared more rounded, less mesenchymal compared with control cells (Fig 5, panel b). Although morphology of the collectivity of the invading cells varied between samples, the considerably reduced invasiveness of EndoA1-depleted cells was apparent (Figs 5E and S6G), whereas proliferation was not significantly affected in vitro (Fig S6D) and ex vivo (Fig 5E). Taken together, these data indicate that EndoA1 contributes to the invasive behavior of the tumor cells in the cerebellar tissue without affecting proliferation.

**Discussion**

We found that HGF-induced c-MET activation alters the abundance of transmembrane and PM-associated proteins in MB cells. The abundance of many of these proteins is reduced by HGF-c-MET activation, indicating either HGF-dependent internalization or attenuated recycling of PM-associated proteins. HGF-induced changes in PM association are increased in MAP4K4-depleted cells and significantly different to control cells for a number of these proteins. Proteins belonging to this group of MAP4K4-regulated proteins are the adhesion receptor CD155 and regulators of FEME. We show that CD155 can contribute to the oncogenic functions of the MB tumor cells by enabling migration, proliferation and tumor cell growth in the brain tissue. We furthermore identified the FEME effector protein EndoA1 as a mediator for HGF-induced collagen invasion in vitro and for tissue invasion ex vivo. The implication of MAP4K4 in PM association of regulators, effectors and targets of endocytic turnover provides a novel conceptual basis for strategies to target the oncogenic phenotype of MB and other RTK-driven solid tumors (Fig 6).

PM-associated proteins were enriched by biotin labeling before mass-spectrometry analysis. This methodology is expected to label predominately extracellularly bound or anchored proteins, transmembrane proteins, and proteins associated with endocytic vesicles. However, internalized biotin may also lead to the purification of intracellular proteins not normally associated with the PM. To exclude non-PM proteins, we either used the TMHMM algorithm to predict transmembrane domains in proteins (29) or a data-based filtering approach, yielding two datasets. Former detects surface proteins. However, it also predicts transmembrane domains of proteins associated with other membrane compartments such as...
the Golgi or ER membranes. The data-based filtering approach selects proteins based on published subcellular localization (30). This approach is not specifically enriching for proteins with transmembrane domains, and it may include non-PM proteins complexed with PM-associated proteins. The TMHMM and data-based annotation approach selected 21% and 8% of all proteins detected in the initial MS analyses, respectively. The TMHMM approach was highly efficient for determining MAP4K4 impact on PM association of transporters and channels, which all contain a TM domain. The data-based annotation approach allows for the comparative analysis of the variations in PM association in all the conditions tested using pathway enrichment analysis.

MAP4K4 implication in HGF-induced internalization of membrane transport proteins and drug transporters (31) indicated a potential therapeutic benefit of targeting this function of MAP4K4 during chemotherapy, which remains one of the first-line treatments for cancer patients. We hypothesized that indirect modulation of drug uptake or extrusion mechanisms could improve drug efficacy. MAP4K4 depletion moderately decreased the sensitivity of DAOY cells to lomustine, but it had no effect on etoposide treatment efficacy. Although of potential interest, our data are inconclusive and susceptibility to additional chemotherapeutic drugs such as cisplatin, which is internalized through LRRC8A (58), should be tested in MAP4K4-depleted cells. Consistent with a potential implication of MAP4K4 in sensitization of tumor cells to chemotherapy, MAP4K4 was recently found to reduce the sensitivity of cervical cancer cells to cisplatin treatment via an autophagy-controlled mechanism (59). The disturbed cell-surface localization of ion channels and transporters could also modify the overall ion homeostasis of the cell. This notion is supported by the subtle alterations in electrical currents we observed in MAP4K4-depleted cells, and it is consistent with previous studies that demonstrated altered electrical conductance properties in tumors compared with healthy tissues (37, 60, 61). We found several ion channels susceptible to MAP4K4 regulation and observed an increased current in MAP4K4-depleted cells, together indicating indirect MAP4K4 control of ion homeostasis via regulated ion channel distribution. The lowered potential in MAP4K4-depleted cells after HGF stimulation could be the consequence of a reduced influx of cations, increased efflux of cations, or increased influx of anions. We observed increased PM association of potassium channels and potassium transport-associated molecules including the P-type cation transporter ATP12A, the Ca$^{2+}$-dependent channels ATP1A3 and KCNMA1 in MAP4K4-depleted cells after HGF stimulation. Thus, MAP4K4 could maintain optimal polarization in HGF-stimulated cells by controlling potassium efflux rates through regulating PM association of K$^+$ transporters. However, whether differential PM association of potassium channels and de-regulated potassium fluxes are at the origin of the electrical disbalance observed in MAP4K4-depleted cells and contribute to the MAP4K4-associated pro-migratory phenotype remains to be determined.

PM association of CD155 is reduced in MAP4K4-depleted cells that are stimulated with HGF. In glioma cells, CD155 mediates adhesion to the extracellular matrix protein vitronectin, promotes FA turnover and FA signaling towards SRC, paxillin, and p130CAS, and thereby contributes to tissue invasion (62). MAP4K4 contributes to FAK activation at the leading edge of migrating cells (14), and our data herein indicate a possibly indirect regulation of this process via the control of CD155 surface expression. Our observation of a more rounded, less mesenchymal morphology in CD155-depleted cells has been described previously in glioma cells (14), and studies in triple-negative aggressive breast cancer cells demonstrated CD155 contribution to the mesenchymal cell state (63). Depletion of CD155 in these cells triggered mesenchymal to epithelial transition and repressed migration and invasion in vitro and in vivo, suggesting that CD155 expression in MB cells could also contribute to migration control indirectly via transcriptional reprogramming. CD155 also represents an attractive therapeutic target because of its ability to inhibit NK cell and CD8+ T-cell activity, thereby contributing to immune evasion of tumor cells (64, 65). Kinase-controlled modulation of CD155 surface expression—as we found herein—could enable this process as rather the abundance, and not the absolute absence or presence, of CD155 at the surface of the cell is critical for its immunomodulatory capabilities (49). Under physiological conditions, CD155 is expressed at low levels, where a balance between its immune activating and inhibitory functions maintains the normal function of immune cells. Thus, the MAP4K4-dependent maintenance of surface expression of CD155 on growth factor-activated cells could not only affect the migratory potential of the cells but also locally (in the tumor microenvironment) repress immune system activation.

Our findings point towards a role of FEME through EndoA1 in the control of the invasive phenotype of MB cells. EndoA1 and A3 are highly expressed in SHH MB compared with other brain tumors and their expression correlates positively with MAP4K4 in this tumor type. This contrasts with clathrin, which correlates negatively with MAP4K4 in SHH MB and with the lack of clear evidence that clathrin-mediated endocytosis is necessary for migration control in our cell models. The role of endophilins in cancer progression is complex and controversial, as endophilins can both promote and reduce cancer cell migration, depending on tumor type (24, 55, 66). We previously found that 5-(N-ethyl-N-isopropyl)amiloride (EIPA), a micropinocytosis inhibitor (67), blocks HGF-induced invasion (14). However, depletion of RAC1 or CTBP1, two upstream activators of micropinocytosis, did not significantly impact HGF-induced motility. This suggests that the pronounced effect of EIPA could be due to the endocytosis-unrelated effects of this drug on ion transport, intracellular pH and cytoskeleton regulation, thus affecting FEME indirectly (24, 55). FEME is involved in the endocytosis of activated receptors at the leading edge of migrating cells (68 Preprint) and fast and ultrafast endocytosis are important for chemotaxis (69). FEME could be involved in the internalization of c-MET, thereby controlling signal transmission and persistence of this receptor (24). Our study identified a possible link between MAP4K4 function and FEME through the regulated PM association of the FEME priming factors SH3KBP1, CIP4 and FBPT1. The observation that MAP4K4 regulates CIP4 PM association and its accumulation in cortical patches provides circumstantial evidence of spatial regulation of CIP4 by MAP4K4. The early endosome marker EEA1 also localizes to these patches, and it is thus possible that one aspect of FEME processing towards early endosomes occurs preferentially there. Depletion of MAP4K4 prevented EEA1 recruitment to these patches, led to an overall decrease in EEA1-positive vesicles and caused accumulation of CIP4 in this location instead. These phenomena
are quite exactly phenocopied by EndoA1 depletion. It is thus possible that MAP4K4 controls FEME by orchestrating a step between FEME priming and trafficking towards early endosomes. Our working model is that MAP4K4 orchestrates PM association of CIP4 from a non-PM-associated subcellular compartment to the “CIP4 patch” in close proximity of or associated with the PM, where also early endosomes enrich. Upon HGF stimulation, CIP4 translocates to the PM, where it is rapidly turned over through EndoA1-dependent FEME before it is recycled back to the PM. Without MAP4K4 function, CIP4 remains associated with the patches, hence the overall amount of PM-associated CIP4 increases. Some key questions remain: (i) does the MAP4K4-dependent mechanism of action involve phosphorylation of one of the components involved in FEME, (ii) is MAP4K4 regulation of CIP4 involved in CIP4-dependent recruitment of EndoA1 to the PM, and (iii) does MAP4K4 control of FEME priming involve the activation of CDC42 downstream of GEFs and GAPs. Elucidation of these mechanisms will be essential to explore therapeutic targeting strategies for specifically repressing MAP4K4 controlled pro-migratory endocytosis.

In conclusion, we found that the HGF-c-MET-MAP4K4 axis regulates PM association and surface expression of proteins affecting different pro-oncogenic mechanisms, including chemotherapy sensitivity, ion homeostasis and cell migration and proliferation. Furthermore, our study indicates the contribution of endophilin A proteins in invasion control downstream of MAP4K4. It thus highlights kinase regulation of the PM proteomic composition as a novel mechanism involved in establishing and maintaining the oncogenic phenotype in MB and other solid tumors. The study provides a conceptual basis for further analysis of the dynamic adaptation of tumor cells to environmental cues by PM proteome modification. Finally, targeting MAP4K4 controlled endocytic activity could represent a novel druggable vulnerability in medulloblastoma cells to restrict tumor growth and dissemination.

Materials and Methods

Cell lines and culture conditions

DAOY human MB cells were purchased from the American Type Culture Collection (ATCC). ONS-76 cells were generously provided by Michael Taylor (SickKids). DAOY and DAOY-LA-EGFP cells were cultured in iMEM complemented with 10% FBS. Medium without FBS is used for starvation and further referred to as serum-free medium (SMF). ONS-76-LA-EGFP cells were cultured in RPMI 1640 complemented with 10% FBS. Medium without FBS is used for starvation. DAOY and ONS-76 Lifeact-enhanced green fluorescent protein (LA-EGFP) cells were produced by lentiviral transduction of DAOY cells with pLenti-LA-EGFP. Cell line authentication and cross-contamination testing were performed by Multiplexion GmbH by single nucleotide polymorphism profiling.

Animals

Pregnant Wild type C57BL/6J mice females were purchased from Janvier Labs and were kept in the animal facilities of the University of Zürich Laboratory Animal Center. Mouse protocols for organotypic brain slice culture were approved by the Veterinary Office of the Canton Zürich.

Generation of CRISPR/Cas9-mediated MAP4K4 knockout cells

MAP4K4 gene-specific single-guide RNA (sgRNA) were designed using Synthego CRISPR design online tool (https://design.synthego.com). Oligos were synthesized by Microsynth and cloned into LentCRISPRv2 transfer plasmid (52961; Addgene) with a single tube restriction and ligation method as described by McComb et al (70). Production of lentiviral vectors and cell transduction was performed as described previously (14). The efficiency of the knockouts was tested by immunoblot. Only the guide with the highest efficiency has been selected for further experiments (sgMAP4K4#1, exon 7, GGGCGGAGAAAATACGTTCA).

Cell-surface labelling

DAOY cells were prepared in four T75 flasks to reach a 70% confluence (per condition and replicates). Standard medium was then replaced with SFM. After 24 h, cells were 85% confluent, and media were replaced with either pre-warmed SFM or pre-warmed SFM supplemented with 20 ng/ml HGF (100-39; PeproTech) for 30 min. EZ-Link-Sulfo-NHS-SS-biotin kit (89881; Thermo Fisher Scientific) was used to surface label DAOY silenced and DAOY_sMAP4K4 cells. In brief, 10 ml EZ-Link-Sulfo-NHS-SS (0.25 mg/ml, diluted in ice-cold PBS) was added at 4°C for 30 min. Biotinylation reaction was terminated by addition of 500 μl quenching solution. Cells from four T75 were collected in a single tube and washed three times with 10 ml ice-cold TBS (700 μl iST Kit Stop solution). The non-bound components of the lysates were washed, eluted, dried and re-solubilized in 20 μl iST Kit LC-Load buffer for MS Analysis.

Liquid chromatography-mass spectrometry analysis

MS analysis was performed on a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific) equipped with a Digital PicoView source
Indirect control of invasion by MAP4K4 via CD155 and EndoA1

C18 Trap Column (100 μl sample, 1% and 0.1% formic acid, 99.9% acetonitrile for channel B. For each composition at the two channels was 0.1% formic acid for channel A (New Objective) and coupled to a M-Class UPLC (Waters). Solvent composition at the two channels was 0.1% formic acid for channel A and 0.1% formic acid, 99.9% acetonitrile for channel B. For each sample, 1 μl of peptides were loaded on a commercial MZ Symmetry C18 Trap Column (100 Å, 5 μm, 180 μm × 20 mm; Waters) followed by nanoEase M2 C18 HSS T3 Column (100 Å, 18 μm, 75 μm × 250 mm; Waters). The peptides were eluted at a flow rate of 300 nl/min by a gradient from B to 27% B in 85 min, 35% B in 5 min and 80% B in 1 min. Samples were acquired in a randomized order. The mass spectrometer was operated in data-dependent mode (DDA), acquiring a full-scan MS spectrum (350–1,400 m/z) at a resolution of 120,000 at 200 m/z after accumulation to a target value of 3,000,000, followed by HCD (higher energy collision dissociation) fragmentation on the 20 most intense signals per cycle. HCD spectra were acquired at a resolution of 15,000 using a normalized collision energy of 25 and a maximum injection time of 22 ms. The automatic gain control was set to 100,000 ions. Charge state screening was enabled. Singly, unassigned, and charge states higher than seven were rejected. Only precursors with intensity above 110,000 were selected for MS/MS. Precursor masses previously selected for MS/MS measurement were excluded from further selection for 30 s, and the exclusion window was set at 10 ppm. The samples were acquired using internal lock mass calibration on m/z 371.1012 and 445.1200. The mass spectrometry proteomics data were handled using the local laboratory information management system (LIMS) (71). The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (72) partner repository with the dataset identifier http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD030597.

Protein identification and label-free protein quantification

The acquired raw MS data were processed by MaxQuant (version 1.6.23), followed by protein identification using the integrated Andromeda search engine (73). Spectra were searched against a Swiss-Prot Homo sapiens reference proteome (taxonomy 9606, version from 2016-12-09), concatenated to its reversed decoy fasta database and common protein contaminants. Carbamidomethylation of cysteine was set as fixed modification, whereas methionine oxidation and N-terminal protein acetylation were set as variables. Enzyme specificity was set to trypsin/P, allowing a minimal peptide length of seven amino acids and a maximum of two missed cleavages. MaxQuant Orbitrap default search settings were used. The maximum false discovery rate was set to 0.01 for peptides and 0.05 for proteins. Label-free quantification was enabled and a 2-min window for the match between runs was applied. In the MaxQuant experimental design template, each file is kept separate in the experimental design to obtain individual quantitative values. Protein fold changes were computed based on intensity values reported in the proteinGroups.txt file. A set of functions implemented in the R package SRMService (http://github.com/protViz/SRMService) was used to filter for proteins with two or more peptides allowing for a maximum of four missing values, and to normalize the data with a modified robust z-score transformation and to compute P-values using the t test with pooled variance. If all protein measurements are missing in one of the conditions, a pseudo fold change was computed replacing the missing group average by the mean of 10% smallest protein intensities in that condition. For data visualization and normalization across all samples, all group comparison correspond has been processed by statistical analysis of all sgMAP4K4 samples (starved and stimulated) versus all sgCTL samples (starved and stimulated).

Chemotherapy sensitivity analysis

400 DAOY sgCTL or sgMAP4K4 were seeded per well in 384 well microplate and incubated 24 h at 37°C. Media were either replaced with low-serum media (1% FBS) or fresh standard culture media (10% FBS) and incubated for another 24 h at 37°C. Cells were treated with either low-serum media or low-serum media supplemented with 20 ng/ml HGF (100-39; PeproTech) or by standard culture media supplemented with lomustine (S1840, 5–100 μM; Selleckchem) or etoposide (S1225, 1 mM–10 μM; Selleckchem). Cell proliferation was quantified after 48 h of incubation using cell proliferation reagent WST-1 (11644807001; Roche) following the manufacturer’s instructions. Sample absorbance was measured against the background using a microplate reader (Biotek Instruments, CytoViva 3) and statistically analyzed using Prism software (GraphPad).

Primary tumor gene expression analysis

Gene expression data were obtained from the R2 genomics and visualization platform (https://r2.amc.nl). Berchtold − 172 − MAS5.0 − u133p2; Normal cerebellum−Roth − 9 − MAS5.0 − u133p2; Tumor Medulloblastoma (SHH) − Pfister − 73 − MAS5.0 − u133p2; Tumor Medulloblastoma−Hsieh − 31 − MAS5.0 − u133p2; Tumor Medulloblastoma−Pfister − 273 − MAS5.0 − u133p2; Tumor Medulloblastoma public−Delattre − 57 − MAS5.0 − u133p2; Tumor Medulloblastoma PLoS One−Kool − 62 − MAS5.0 − u133p2; Tumor Medulloblastoma−Gilbertson − 76 − MAS5.0 − u133p2 were used to analyze CLIC1 expression in Medulloblastoma versus normal brain tissues. The Tumor Medulloblastoma−Cavalli − 763 − rna_sketch−hugene11T dataset with 763 primary medulloblastoma samples was used for Kaplan Meier survival analysis relative to CLIC1 mRNA expression levels. Molecular pathways correlating with MAP4K4 gene expression have been determine using the R2 genomics and visualization platform built-in KEGG PathwayFinder by Gene correlation tool. Transcriptomic and proteomic data were obtained from the ProTrack pediatric brain tumor database of the Clinical proteomic Tumor Analysis Consortium (CPTAC) and Children’s Brain Tumor Tissue Consortium (CBTTC).

Patch-clamp analysis

DAOY sgCTL or sgMAP4K4 were seeded in a 35 mm dish to reach 20% confluence. After 6 h of incubation in standard culture condition, the medium was replaced with starvation medium. The next day, cells were treated with either SFM or SFM supplemented with 20 ng/ml HGF for 30 min. Cells were kept in the patch chamber for 30 min. Whole-cell recordings at room temperature were performed on DAOY sgCTL and sgMAP4K4 cells using patch pipettes of −7 MΩ. The patch pipette solution contained (in mM) 95 K-gluconate, 30 KCl,
4.8 Na₂HPO₄, 1.2 NaH₂PO₄, 5 glucose, 2.38 MgCl₂, 0.76 CaCl₂, 1 EGTA, and 3 K-ATP. The bath solution contained (in mM) 142 NaCl, 1.8 MgCl₂, 1.8 CaCl₂, 10 Hepes, and 3 KCl. Compensations and measurements were done within 30 s after obtaining whole cell to avoid drastic changes in cytoplasmic ionic concentration.

Gene annotation and pathway enrichment analysis

Gene annotation and pathway enrichment analyses on the surface-proteomics results were performed using the Metascape webtool (https://metascape.org) developed by Zhou et al (39). Transmembrane proteins were annotated using the TMHMM prediction algorithm (29). We performed pathway enrichment using all pathway enrichment categories, standard settings and using all proteins identified by mass-spectrometry as background genes.

siRNA transfections

100,000 DAOY or ONS-76 cells were seeded per well in six-well plates. The following day, cells were transfected with 10 nM siRNAs using Lipofectamine RNAiMAX Transfection Reagent (13778075; Invitrogen) plus. siRNA used are referenced in Table S5. After 6 h, the media were changed, and cells were kept in culture overnight for downstream analyses.

qRT-PCR analysis of gene expression

100,000 siRNA transfected DAOY cells (24 h after transfection) were seeded per well in six-well plates and incubated overnight. For quantitative real-time PCR (qRT-PCR) analysis of target genes, total RNA was isolated using QIAGEN RNeasy Mini Kit (74106; QIAGEN). 1 μg mRNA was converted to cDNA using the high-capacity cDNA Reverse Transcription Kit (4368813; Applied Biosystems). qRT-PCR was performed using PowerUp Syber Green (A25776; Applied Biosystems) under conditions optimized for the ABI7900HT instrument. The primers used are referenced in Table S5. After 48 h, the media were changed, and cells were incubated in SFM ± HGF 20 ng/ml for DAOY spheroids or standard culture media for ONS-76 spheroids was added per well. Cells were incubated at 37°C for 16 h until fixation with 4% paraformaldehyde. A 1:5,000 dilution of Hoechst (B2883; Sigma-Aldrich) was added to stain DNA for nuclei visualization. Images of spheroids and invading cells were acquired on an Operetta CLS High-Content Analysis System (HH16000000; PerkinElmer) at 5× magnification using the Dapi (405 nm) channel. Spheroids were localized in the well by acquiring three z-planes with 250 μm z-spacing. Localized spheroids were re-scanned by acquiring 16Hoechst-stained z-planes with 25 μm z-spacing and a maximum intensity projection of each spheroid was computed and used for further analysis. Using Harmony software (PerkinElmer), spheroids and invading cells were delineated based on fluorescence threshold. The distance from the center of the spheroid was calculated, and the sum of the cell invasion was determined as the sum of all individual values acquired per well.

3D-cell viability/proliferation (Cell TiterGlo) assay

Cell viability was determined using CellTiter-Glo 3D cell viability assay (#G9242, HG9682; Promega). 500 siRNA transfected cells/25 μl were seeded in U-low adhesion (#4516; Corning) 384-well plate. After 48 h, the CellTiter-Glo 3D reagent was added (volume/volume) following the manufacturer’s instructions. Plates were incubated at room temperature under agitation for 30 min and luminescence representing the number of viable cells was quantified with a Cytation 3 imaging reader (BioTek).

Cell proliferation assay

1,000 DAOY cells were seeded in 96-well plates (655087; Greiner Bio-One). The following day, cells were transfected according to the protocol described above. 6 h after transfection, the medium was replaced with serum-free medium. For time point 0, WST reagent was added to the corresponding well and incubated 30 min at 37°C. Absorbance at 440 nm was measured using a microplate reader (Biotek Instruments, Cytation 3). 20 ng/ml HGF was added to remaining time points and incubated for 24, 48, and 72 h. At the end of each time point, WST reagent was added to the corresponding well and absorbance measured. Each day the medium was replaced with fresh serum-free medium supplemented with HGF. Changes in absorbance over time were analyzed using Prism 9 software (GraphPad).

Single-cell motility assay

1,000 siRNA transfected ONS-76-LA-EGFP cells were seeded in 96 well microplates (655098; Greiner Bio-one) previously coated with
Ex vivo organotypic cerebellum slice culture (OCSC)

Ex vivo OCSC was carried out essentially as described previously (56). Wild-type C57BL/6J mice were euthanized at postnatal day 8–10. Cerebella were dissected and kept in ice-cold Gey’s balanced salt solution containing kynurenic acid (GBSSK) and then embedded in 2% low melting point agarose gel. 350-μm thick sections were cut using a vibratome (VT1200S; Leica) and transferred on inserts (PICM03050; Merck Millipore) for further in vitro culture. Slices were kept in culture and monitored for 15 d, and media were changed daily for the first week and once in 2 d thereafter. Spheroids of DAOY-LA-EGFP or ONS-76-LA-EGFP cells transfected with siCTL or CD155 were implanted and then grown in the slices for 48 h. For HGF stimulation, the feeding medium was supplemented with 20 ng/ml HGF (100-39; PeproTech). Transwell migration was allowed for 18 h, and cells were then fixed in 4% paraformaldehyde (28908; Thermo Fisher Scientific) in PBS for 10 min. Fixed cells were stained with DAPI for 15 min. The remaining non-invading cells on the upper surface of the membrane were removed using a cotton swab. Images of DAPI-stained nuclei were acquired using an Axio Observer 2 plus fluorescence microscope (Zeiss) at 5× magnification. Nuclei were counted on the membrane areas using ImageJ software and plotted on Prism 9 software (GraphPad).

Immunofluorescence analysis

1,500 transfected cells (24 h after transfection) were seeded in 384-well plate (781090; Greiner Bio-One) and incubated overnight in normal growth conditions. Cells were starved in low serum condition (1% FBS) for 24 h and treated with 20 ng/ml HGF for 10- or 30-min. Cells were fixed directly with 4% PFA at 37°C for 20 min. Between all subsequent steps, cells were washed five times with PBS using the 50 TS washer (BioTek). Cells were permeabilized with 0.05% saponin for 20 min at RT. Blocking was performed during 1 h at RT with 1% FBS. Primary antibody (Table S7) solution was added to the sample and shaken at 100 rpm on a HS 500 horizontal reciprocating shaker (Janke & Kunkel) for 2 h. Secondary antibody (Table S7) solutions were added to the sample and shaken at 100 rpm for 2 h. Nucleic acids were stained with Hoechst-33342 (B2883, 12,000 in PBS; Sigma-Aldrich) for 20 min at RT. Image acquisition was performed using the Operetta CLS High-Content Analysis System (HH1600000; PerkinElmer) at 40× magnification. Nine fields per well with 9 z-planes with 500 nm z-spacing were acquired per site. Maximum intensity projection was computed and used for subsequent analysis. For puncta quantification, EEA1 or LAMP1 signals were segmented using the Harmony software (PerkinElmer) and quantified. The total number of puncta was referred to the number of cells present per field.

Statistical analysis

The samples sizes and statistical tests were selected based on previous studies with similar methodologies. Sample sizes were not determined using statistical methods. Statistical analysis was performed using the Prism 9 software (GraphPad). One-way ANOVA repeated measures test using Tukey’s multiple comparison was used as the internal loading control. HRP-linked secondary antibodies (1:2,000) were used to detect the primary antibodies. Chemiluminescence detection was carried out using ChemiDoc Touch Gel imaging system (Bio-Rad). The integrated density of detected bands was quantified using Image Lab software (Bio-Rad).
performed for multiple comparisons. P-value <0.05 were considered significant (* = P < 0.05, ** = P < 0.01, *** = P < 0.001, **** = P < 0.0001, ns, not significant).

Data Availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (72) partner repository with the dataset identifier http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXDD030597.

Supplementary Information

Supplementary Information is available at https://doi.org/10.26508/lsa.202201380.

Acknowledgements

We thank Dr. Paolo Nanni, Dr. Jonas Grossman and Claudia Fortes from the Functional Genomic Center Zürich for their help and support for Mass Spectrometry analysis. We like to thank the UZH electrophysiology facility (e-phae) for their technical support. Imaging was performed with equipment maintained by the Center for Microscopy and Image Analysis, University of Zurich. This study was supported by grants from the Swiss National Science Foundation (SNF_31003A_165860/1, SNF_310030_188793) to M Baumgartner and from the Childhood Cancer Foundation to MA Grotzer.

Author Contributions

C Capdeville: conceptualization, data curation, formal analysis, investigation, visualization, methodology, and writing—original draft.
L Russo: investigation.
D Penton: investigation and methodology.
J Migliavacca: formal analysis, investigation, and methodology.
M Zecevic: validation and investigation.
A Gries: formal analysis, investigation, and methodology.
SCF Neuhauss: funding acquisition and methodology.
MA Grotzer: funding acquisition.
M Baumgartner: conceptualization, formal analysis, supervision, funding acquisition, investigation, visualization, methodology, project administration, and writing—original draft, review, and editing.

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

References

1. Almén MS, Nordström KJF, Fredriksson R, Schiøtt HB (2009) Mapping the human membrane proteome: A majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biol 7: 50. doi:10.1186/1741-7007-7-50
2. Ye X, Kaczmarczyk JA, Luke B, Saul RG, Whiteley GR, Nissley DV, Blonder J (2020) Cell surface protein enrichment for biomarker and drug target discovery using mass spectrometry-based proteomics Proteomic and Metabolomic Approaches to Biomarker Discovery. Netherlands: Elsevier. 409–420.
3. Orlando K, Guo W (2009) Membrane organization and dynamics in cell polarity. Cold Spring HarbPerspect Biol 1: a001321. doi:10.1101/cshperspect.a001321
4. Rodriguez-Furlan C, Minina EA, Hicks GR (2019) Remove, recycle, degrade: Regulating plasma membrane protein accumulation. Plant Cell 31: 2833–2854. doi:10.1105/tpc.19.00433
5. Schmid SL (2017) Reciprocal regulation of signaling and endocytosis: Implications for the evolving cancer cell. J Cell Biol 216: 2623–2632. doi:10.1083/jcb.201705017
6. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646–674. doi:10.1016/j.cell.2011.02.013
7. Mosesson Y, Mills GB, Yarden Y (2008) Derailed endocytosis: An emerging feature of cancer. Nat Rev Cancer 8: 835–850. doi:10.1038/nrc2521
8. Skowron P, Ramaswamy V, Taylor MD (2015) Genetic and molecular alterations across medulloblastoma subgroups. J Mol Med (Berl) 93: 1075–1084. doi:10.1007/s00109-015-1333-8
9. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, et al (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29: 1408–1414. doi:10.1200/ JCO.2009.27.4324
10. Northcott PA, Dubuc AM, Pfister S, Taylor MD (2012) Molecular subgroups of medulloblastoma. Expert Rev Neurother 12: 871–884. doi:10.1586/ern.12.66
11. Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA (2020) Medulloblastomics revisited: Biological and clinical insights from thousands of patients. Nat Rev Cancer 20: 42–56. doi:10.1038/s41568-019-0223-8
12. Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, et al (2019) Challenges to curing primary brain tumours. Nat Rev Clin Oncol 16: 509–520. doi:10.1038/s41571-019-0177-5
13. Santhanam Kumar K, Tripolitsioti D, Ma M, Grählert J, Egli KB, Fiaschetti G, Shalaby T, Grotzer MA, Baumgartner M (2015) The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma. Springerplus 4: 19. doi:10.1186/s40064-015-0784-2
14. Tripolitsioti D, Kumar KS, Neve A, Migliavacca J, Capdeville C, Rushing EJ, Ma M, Kijima N, Sharma A, Pruschy M, et al (2018) MAP4K4 controlled integrin β1 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells. Oncotarget 9: 23220–23236. doi:10.18632/oncotarget.25294
15. Hood JD, Chershaw DA (2002) Roles of integrin in cell invasion and migration. Nat Rev Cancer 2: 91–100. doi:10.1038/nrc727
16. de Franceschi N, Hamidi H, Alanko J, Sahgal P, Ivaska J (2015) Integrin trafficking: The update. J Cell Sci 128: 839–852. doi:10.1242/jcs.161653
17. Kermorgant S, Zicha D, Parker PJ (2004) PKC controls HGF-dependent c-Met trafficking, signalling and cell migration. EMBO J 23: 3721–3734. doi:10.1038/sj.emboj.7600396
18. Alanko J, Mai A, Jacquemet G, Schauer K, Kaukonen R, Saari M, Goud B, Ivaska J (2015) Integrin endosomal signalling suppresses anoikis. Nat Cell Biol 17: 1412–1421. doi:10.1038/ncb3520
19. Kjaerulf O, Brodin L, Jung A (2011) The structure and function of endophilin proteins. Cell Biochem Biophys 60: 137–154. doi:10.1007/s12013-010-9137-5
20. Masuda M, Takeda S, Sone M, Ohki T, Mori H, Kamioka Y, Mochizuki N (2006) Endophilin BAR domain drives membrane curvature by two newly identified structure-based mechanisms. EMBO J 25: 2889–2897. doi:10.1038/sj.emboj.7601176
Indirect control of invasion by MAP4K4 via CD155 and EndoA1

Cooperates with potassium channel EQ2 to promote medulloblastoma growth. J Exp Med 217: 324–387. doi:10.1084/jem.20190971

Liu F, Zhang T, Zou S, Jiang B, Hua D (2015) B7-H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer. Mol Med Rep 12: 5455–5460. doi:10.3892/mmr.2015.4050

Zhao Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanasechuk O, Benner C, Chanda SK (2019) Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 10: 1523. doi:10.1038/s41467-019-09324-6

Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, et al (2017) A subcellular map of the human proteome. Science 356: eaal3321. doi:10.1126/science.aal3321

Defelice LJ (2004) Transporter structure and mechanism. Trends Neurosci 27: 352–359. doi:10.1016/j.tins.2004.04.007

Hoffmann EK, Lambert IH (2014) Ion channels and transporters in the development of drug resistance in cancer cells. Philos Trans R Soc Lond B Biol Sci 369: 20130109. doi:10.1098/rstb.2013.0109

Giacomini KM, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215–236. doi:10.1038/nrd3028

Deeley RG, Westlake C, Cole SP (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849–889. doi:10.1152/physrev.00015.2005

Sprensen BH, Nielsen D, Thorsteinsdottir UA, Hoffmann EK, Lambert IH (2016) Downregulation of LRRCA8 protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Am J Physiol Cell Physiol 310: C857–C873. doi:10.1152/ajpcell.00256.2015

Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D’Angio G, Wechsler-Jentzsch K, et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81: 690–698. doi:10.3171/jns.1994.81.5.0690

Greenberg HS, Chamberlain MC, Glantz MJ, Wang S (2001) Adult medulloblastoma: Multigenet chemotherapy. Neuro Oncol 3: 29–34. doi:10.1093/neuonc/3.1.29

Payne SL, Levin M, Oudin MJ (2019) Bioelectric control of metastasis in solid tumors. Bioelectricity 1: 114–130. doi:10.1089/bioe.2019.0013

Kučan Brici P, Lenac Rovi T, Cimiano G, Scuderi P, Mandelboim O, Jonić S (2019) Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 16: 40–52. doi:10.1038/s41423-018-0168-y

Kumar KS, Pillong M, Kunje J, Burghardt I, Weller M, Grotzer MA, Schneider G, Baumgartner M (2015) Computer-assisted quantification of motile and invasive capabilities of cancer cells. Sci Rep 5: 15338. doi:10.1038/srep15338

Roper SJ, Linke F, Scotting PJ, Coyle B (2021) 3D spheroid models of paediatric SHH medulloblastoma mimick tumour biology, drug response and metastatic dissemination. Sci Rep 11: 4259–4317. doi:10.1038/s41598-017-05573-w

Neve A, Santha Kumar K, Tripolitsioti D, Grotzer MA, Baumgartner M (2017) Investigation of brain tissue in paediatric SHH medulloblastoma mimic tumour biology, drug response and metastatic dissemination. Sci Rep 7: 5297–5312. doi:10.1038/s41598-017-05573-w

Cavalieri FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Loo B, Garzia L, Torcchia J, Nor C, Morrissy AS, et al (2017) Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31: 737–754.e6. doi:10.1016/j.ccell.2017.05.005

Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, Krek A, Ma W, Zhu Y, Ji J, et al (2020) Integrated proteogenomic characterization...
across major histological types of pediatric brain cancer. Cell 183: 1962–1985.e31. doi:10.1084/jem.2020.10.044

55. Casamento A, Boucrot E (2020) Molecular mechanism of fast endophilin-mediated endocytosis. Biochem J 477: 2327–2345. doi:10.1042/BCJ20190342

56. Cendrowski J, Mamiriska A, Miaczynska M (2016) Endocytic regulation of cytokine receptor signaling. Cytokine Growth Factor Rev 32: 63–73. doi:10.1016/j.cytogfr.2016.07.002

57. Liberali P, Kakkonen E, Turacchio G, Valente C, Spaar A, Perinetti G, Cendrowski J, Mamińska A, Miaczynska M (2016) Endocytic regulation of cancer cells.

58. Sørensen BH, Dam CS, Stürup S, Lambert IH (2016) Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells. J Inorg Biochem 160: 287–295. doi:10.1016/j.jinorgbio.2016.04.004

59. Huang H, Han Q, Zheng H, Liu M, Shi S, Zhang T, Yang X, Li Z, Xu Q, Guo H, et al (2022) J. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. EMBO J 27: 970–981. doi:10.1038/emboj.2008.59

60. Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, Penning TM, Lin HK (2009) Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 69: 1077–1090. doi:10.1002/pros.20960

61. Pollak J, Rai KG, Funk CC, Arora S, Lee E, Zhu J, Price ND, Paddison PJ, Ramirez JM, Rostomily RC (2017) Ion channel expression patterns in glioblastoma stem cells with functional and therapeutic implications for malignancy. PLoS One 12: e0172884. doi:10.1371/journal.pone.0172884

62. Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG (2005) CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res 65: 10930–10937. doi:10.1158/0008-5472.CAN-05-1890

63. Zheng Q, Gao J, Yin P, Wang W, Wang B, Li Y, Zhao C (2020) CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer. Cancer Sci 111: 383–394. doi:10.1111/cas.14276

64. Okumura G, Iguchi-Manaka A, Murata R, Yamashita-Kanemaru Y, Shibuya A, Shibuya K (2020) Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells. J Exp Med 217: 1. doi:10.1084/jem.20191290

65. He W, Zhang H, Han F, Chen X, Lin R, Wang W, Qiu H, Zhuang Z, Liao Q, Zhang W, et al (2017) CD155ST/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer. Cancer Res 77: 6375–6388. doi:10.1158/0008-5472.CAN-17-0381

66. Majumdar S, Gong EM, Di Vizio D, Dreyfuss J, Degraff DJ, Hager MH, Park PJ, Bellmunt J, Matusik RJ, Rosenberg JE, et al (2013) Loss of SH3GL2/endothelin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia 15: 749–760. doi:10.1593/neo.121956

67. Kabayama H, Takeuchi M, Taniguchi M, Tokushige N, Kozaki S, Mizutani A, Nakamura T, Mikoshiba K (2011) Syntaxin 1B suppresses macropinocytosis and semaphorin 3A-induced growth cone collapse. J Neurosci 31: 7357–7364. doi:10.1523/JNEUROSCI.2718-10.2011

68. Mondal S, Powers I, Narayan K, Botterbusch S, Baumgart T (2020) Endophilin recruitment via GPCR interactions enables membrane curvature generation in the absence of anionic lipids. BioRxiv 0711: 198937. doi:10.1101/2020.07.11.198937Preprint posted July 12, 2020.

69. Watanabe S, Boucrot E (2017) Fast and ultrafast endocytosis. Curr Opin Cell Biol 47: 64–71. doi:10.1016/j.jeb.2017.02.013

70. McComb S, Aguadé-Gorgonió J, Harder L, Marovca B, Cario G, Eckert C, Schrappe M, Stankul, M, Von Stackelberg A, Bourquin JP, et al (2016) Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL. Sci Transl Med 8: 339ra70. doi:10.1126/scitranslmed.aad2986

71. Türker C, Akal F, Joho D, Panse C, Barkow-Oesterreicher S, Rehrauer H, Schlappbach R (2010) B-Fabric Proceedings of the 13th International Conference on Extending Database Technology - EDBT [R8S2Q1M7]10 717. ACM Press.

72. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, Inuganti A, Griss J, Mayer G, Eisenacher M, et al (2019) The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res 47: D442–D450. doi:10.1093/nar/gky106

73. Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26: 1367–1372. doi:10.1038/nbt.1511